Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,590JPY
1 Mar 2017
Change (% chg)

-- (--)
Prev Close
¥2,590
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,455,928
52-wk High
¥2,750
52-wk Low
¥2,192

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.86
Market Cap(Mil.): ¥1,815,424.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.54

Financials

  4568.T Industry Sector
P/E (TTM): 28.74 29.14 29.88
EPS (TTM): 89.08 -- --
ROI: 3.57 13.58 13.08
ROE: 4.74 14.48 14.24

BRIEF-EMA recommends approval of Daiichi Sankyo's anticoagulant

* EU Medicines Agency recommends approval Of Daiichi Sankyo's anticoagulant Edoxaban

Feb 24 2017

BRIEF-Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial

* Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma

Feb 17 2017

BRIEF-Daiichi Sankyo to close Japan research unit Asubio Pharma

* Says move aimed at further reorganising its research and development structure Source text for Eikon: Further company coverage: (Reporting By Chris Gallagher)

Feb 10 2017

BRIEF-Daiichi Sankyo initiates phase 1/2 study of novel antibody drug conjugate in patients unresectable breast cancer

* Daiichi sankyo initiates phase 1/2 study of novel antibody drug conjugate u3-1402 in patients with her3-positive metastatic or unresectable breast cancer Source text for Eikon: Further company coverage:

Jan 18 2017

BRIEF-Kite Pharma establishes strategic partnership with Daiichi Sankyo

* Kite Pharma establishes strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (kte-c19) in Japan

Jan 09 2017

Kite Pharma partners with Japan's Daiichi for cancer therapy

Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments.

Jan 09 2017

Kite Pharma partners with Japan's Daiichi for cancer therapy

Jan 9 Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments.

Jan 09 2017

BRIEF-Portola Pharmaceuticals expands pact with Daiichi Sankyo

* Portola Pharmaceuticals expands clinical collaboration agreement with Daiichi Sankyo worth up to $25 million to develop ANDEXXA (Andexanet Alfa) in Germany

Nov 01 2016

BRIEF-Pieris Pharmaceuticals to receive GLP Tox payment in Daiichi Sankyo collaboration

* Pieris Pharmaceuticals to receive GLP tox milestone payment in Daiichi Sankyo collaboration

Oct 26 2016

BRIEF-Daiichi Sankyo Co and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond

* Daiichi And Inspirion Delivery Sciences LLC announce U.S. Licensing agreement for morphabond formulated with sentrybond abuse-deterrent technology

Oct 25 2016

More From Around the Web

Earnings vs. Estimates